Biocryst Pharmaceuticals (BCRX) Net Cash Flow Growth (5y) (2015 - 2026)
Biocryst Pharmaceuticals (BCRX) Net Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn |
| 3 | Zoetis | 31.45 Bn | 29.77 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.76% |
| Mar 31, 2026 | 31.22% |
| Dec 31, 2025 | -15.48% |
| Sep 30, 2025 | 45.74% |
| Jun 30, 2025 | -15.38% |
| Mar 31, 2025 | 14.97% |
| Dec 31, 2024 | -36.70% |
| Sep 30, 2024 | 45.73% |
| Jun 30, 2024 | -26.17% |
| Mar 31, 2024 | -37.48% |
| Dec 31, 2023 | -9.46% |
| Sep 30, 2023 | -25.49% |
| Jun 30, 2023 | 9.04% |
| Mar 31, 2023 | -95.76% |
| Dec 31, 2022 | 23.34% |
| Sep 30, 2022 | -18.52% |
| Jun 30, 2022 | -30.61% |
| Mar 31, 2022 | -31.99% |
| Dec 31, 2021 | 90.00% |
| Sep 30, 2021 | -19.16% |